PE20212270A1 - Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas - Google Patents

Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas

Info

Publication number
PE20212270A1
PE20212270A1 PE2021001490A PE2021001490A PE20212270A1 PE 20212270 A1 PE20212270 A1 PE 20212270A1 PE 2021001490 A PE2021001490 A PE 2021001490A PE 2021001490 A PE2021001490 A PE 2021001490A PE 20212270 A1 PE20212270 A1 PE 20212270A1
Authority
PE
Peru
Prior art keywords
compound
formulations
enhanced bioavailability
fluoro
refers
Prior art date
Application number
PE2021001490A
Other languages
English (en)
Inventor
Akm Nasir Uddin
Mandar Vasant Dali
Onkar Shripad Vaze
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of PE20212270A1 publication Critical patent/PE20212270A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA AMORFA DEL COMPUESTO 5-FLUORO-2-(6-FLUORO-2-METIL-1H-BENCIMIDAZOL-1-IL)-N-[4-(TRIFLUOROMETIL)FENIL]PIRIMIDIN-4,6-DIAMINA DENOMINADO COMPUESTO A. TAMBIEN SE REFIERE A UNA DISPERSION SOLIDA AMORFA QUE COMPRENDE LA FORMA AMORFA DEL COMPUESTO A Y UN POLIMERO ESTABILIZANTE TAL COMO POLIVINILPIRROLIDONA O ACETATO SUCCINATO DE HIDROXIPROPILMETILCELULOSA, DONDE LA CANTIDAD EN PESO DEL COMPUESTO A Y LA CANTIDAD EN PESO DEL POLIMERO ESTABILIZANTE ESTA EN UN INTERVALO DE ENTRE 10:90 Y 40:60.
PE2021001490A 2019-03-11 2020-03-09 Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas PE20212270A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962816402P 2019-03-11 2019-03-11
PCT/US2020/021648 WO2020185648A1 (en) 2019-03-11 2020-03-09 Compound form having enhanced bioavailability and formulations thereof

Publications (1)

Publication Number Publication Date
PE20212270A1 true PE20212270A1 (es) 2021-11-30

Family

ID=70166162

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001490A PE20212270A1 (es) 2019-03-11 2020-03-09 Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas

Country Status (19)

Country Link
US (1) US20220185795A1 (es)
EP (1) EP3938368B1 (es)
JP (1) JP2022524424A (es)
KR (1) KR20210151061A (es)
CN (1) CN113853374A (es)
AU (1) AU2020235825A1 (es)
BR (1) BR112021017353A2 (es)
CA (1) CA3131801A1 (es)
CL (1) CL2021002365A1 (es)
CO (1) CO2021011836A2 (es)
EA (1) EA202192167A1 (es)
EC (1) ECSP21067104A (es)
HU (1) HUE062796T2 (es)
IL (1) IL286163A (es)
MX (1) MX2021010906A (es)
PE (1) PE20212270A1 (es)
PL (1) PL3938368T3 (es)
SG (1) SG11202109503TA (es)
WO (1) WO2020185648A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3131249A1 (en) * 2019-02-28 2020-09-03 Ptc Therapeutics, Inc. 5-fluoro-2-(6fluoro-2-methyl-1h-benzo(d)imidazol-1-yl)-n4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine dor treating a multiple myeloma
EP3947379A4 (en) * 2019-03-27 2022-12-21 PTC Therapeutics, Inc. COMBINATIONS FOR USE IN A METHOD OF TREATMENT OF SARCOMA

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035349B1 (ru) * 2012-11-21 2020-05-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1

Also Published As

Publication number Publication date
BR112021017353A2 (pt) 2021-11-16
WO2020185648A1 (en) 2020-09-17
KR20210151061A (ko) 2021-12-13
ECSP21067104A (es) 2021-11-18
CN113853374A (zh) 2021-12-28
CA3131801A1 (en) 2020-09-17
US20220185795A1 (en) 2022-06-16
EA202192167A1 (ru) 2022-01-12
IL286163A (en) 2021-10-31
SG11202109503TA (en) 2021-09-29
PL3938368T3 (pl) 2023-12-27
EP3938368B1 (en) 2023-06-07
MX2021010906A (es) 2021-10-01
CO2021011836A2 (es) 2021-12-10
JP2022524424A (ja) 2022-05-02
CL2021002365A1 (es) 2022-04-22
EP3938368A1 (en) 2022-01-19
AU2020235825A1 (en) 2021-09-30
HUE062796T2 (hu) 2023-12-28

Similar Documents

Publication Publication Date Title
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
CY1125697T1 (el) Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων
PE20170662A1 (es) Compuestos de aminopiridiloxipirazol
EA201892734A1 (ru) ПРОИЗВОДНЫЕ АЗАБЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ pI3K BETA
CO6390084A2 (es) Composiciones insecticidas estables y métodos para producir las mismas
TWD192468S (zh) 真空吸塵器（三十九）
UY36054A (es) “CROMENO Y 1,1a,2,7b–TETRAHIDROCICLOPROPA[C]CROMENOPIRIDOPIRAZINADIONAS NOVEDOSAS”.
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
CY1125004T1 (el) Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας
PE20212270A1 (es) Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas
TWD198853S (zh) 口腔保健用具
MX2015010106A (es) Moduladores de la proteina activadora de 5-lipoxigenasa.
AR110249A1 (es) Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo
CO2017008156A2 (es) Derivados de 1-(4-(4-(pirimidin-5-il)tiazol-5-il)piperazin-1-il)etan-1-ona y análogos de piridina de los mismos como moduladores del receptor cxcr3, composiciones que los comprenden y métodos de elaboración
CO2018007663A2 (es) Compuestos indolinonas y su uso en el tratamiento de enfermedades fibróticas
TWD192692S (zh) 真空吸塵器（五十三）
PH12020550703A1 (en) Sulfonamide compounds and use thereof
TWD192465S (zh) 真空吸塵器（九）
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta
CY1126071T1 (el) Φαρμακευτικα σκευασματα αναλογων κυκλοσπορινης
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
UY36546A (es) “ciclopropabenzofuranil-piridopirazindionas novedosas”.
TWD206657S (zh) 喇叭
MX2020004202A (es) Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas.
UY38017A (es) Polimorfos de 4-[5-(3,5-dicloro-4-fluorofenil)-4,5-dihidro-5-(trifluorometil)-3-isoxazolil]-n-(2-etil-3-oxo-4-isoxazolidinil)-2-metilbenzamida